#119: Voices of Leadership. CEO of MS South Africa on Patient Support and the Future of MS Care
If you’re living with MS or care about the global MS community, it’s essential to understand that while MS is one disease, it brings very different challenges depending on where in the world you are — and South Africa is no exception. In this episode, I want to give you an honest and comprehensive look […]
#115: Stem Cell Therapy for MS – A Conversation with Prof. Christoph Heesen
In this episode, I speak with Prof. Christoph Heesen from the University Medical Center Hamburg-Eppendorf (UKE) in Germany about stem cell therapy for people with multiple sclerosis. Christoph shares his clinical experience and gives a detailed overview of how the treatment works, who it may benefit, and what risks are involved. We also discuss a […]
#112: MSIF – Past, Present and Future with Peer Baneke and Lydia Makaroff
The Multiple Sclerosis International Federation (MSIF) plays a vital role in uniting the global MS community to improve the lives of people affected by multiple sclerosis. In this inspiring interview, Peer Baneke, former CEO, and Lydia Makaroff, the new CEO, share their insights on past milestones, current challenges, and the future vision of MSIF. From […]
#085: ECTRIMS Special on innovative MS rehabilitation for better quality of life
Rehabilitation for multiple sclerosis (MS) is rapidly evolving, with exciting new approaches tailored to the unique needs of people with progressive MS (PwPMS). Recent studies have explored how various types of personalized therapies can improve both physical and mental well-being, offering a wider range of options for supporting a fulfilling, active life with MS. The […]
#083: ECTRIMS Special on De-escalation and discontinuation of therapies for MS – What does it mean and how can it work?
Hello and welcome to another summary of ECTRIMS 2024, this time on the topic of de-escalation and discontinuation of therapy. There was a scientific session on this topic with six lectures, moderated by Dr. Melinda Magyari and Prof. Bernhard Hemmer. And there were also individual posters. Except for one talk about NMOSD and MOGAD, all […]
#080: B-Cell Depletion – Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta, Bonspri), Rituximab (Mabthera, Rituxan), Ublituximab (Briumvi) for active RRMS and SPMS, and early PPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#078: Cladribine (Mavenclad, Leustat, Litak) for highly active MS
Cladribine (Mavenclad, Leustat, Litak) is an induction therapy the supresses the immun system and is used for highly active MS.
#076: Alemtuzumab (Lemtrada, Campath) for highly active Multiple Sclerosis
Alemtuzumab (Lemtrada, Campath) is a DMT to treat highly active MS and has long-lasting effects and potential severe side effects.
#074: S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
#072: Natalizumab (Tysabri, Tyruko) for active relapsing remitting MS
Interferon-beta (Avonex, Betaferon, Extavia, Plegrid,y Rebif) is used as a disease-modifying therapy for mild to moderate RRMS, CIS & SPMS.
